Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-S... Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0384 | -10.5755990085 | 0.3631 | 0.3631 | 0.3247 | 2000 | 0.3247 | CS |
| 4 | -0.0384 | -10.5755990085 | 0.3631 | 0.3631 | 0.3247 | 2000 | 0.3247 | CS |
| 12 | -0.0553 | -14.5526315789 | 0.38 | 0.38 | 0.3247 | 500 | 0.3247 | CS |
| 26 | 0.16895 | 108.475120385 | 0.15575 | 0.38 | 0.15575 | 1652 | 0.32888675 | CS |
| 52 | 0.132 | 68.5002594707 | 0.1927 | 0.38 | 0.15575 | 1310 | 0.24786815 | CS |
| 156 | -2.0353 | -86.2415254237 | 2.36 | 2.36 | 0.15575 | 1647 | 0.49554219 | CS |
| 260 | -1.9653 | -85.8209606987 | 2.29 | 2.36 | 0.15575 | 1622 | 0.49738646 | CS |
Mr. Dragon
2分前
ty3
2分前
MineInvestor01
3分前
Smartypants2
4分前
Smartypants2
4分前
LA4321
5分前
Oleblue
5分前
otcmoneydoubler
6分前
TommyBoy100
9分前
Smartypants2
10分前
DredLock
10分前
Smartypants2
11分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。